Type 1 Diabetes

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease in which the immune system selectively destroys the insulin-producing beta cells of the pancreatic islets of Langerhans, resulting in absolute insulin deficiency. Unlike type 2 diabetes, which involves insulin resistance with relative deficiency, T1DM leaves the body entirely unable to produce meaningful insulin without external supplementation. It accounts for approximately 5–10% of all diabetes cases worldwide and requires lifelong insulin therapy to sustain life. Although it most commonly appears in childhood and adolescence, T1DM can develop at any age — including in adults, where it is frequently misdiagnosed as type 2 diabetes.

  1. What Is Type 1 Diabetes
  2. Genetics and Risk Factors
  3. Pathogenesis and Autoimmunity
  4. Autoantibodies and Stages of T1DM
  5. Diagnosis
  6. Diabetic Ketoacidosis (DKA)
  7. Treatment and Insulin Therapy
  8. Continuous Glucose Monitoring and Closed-Loop Systems
  9. Novel and Emerging Therapies
  10. Research Papers
  11. Connections
  12. Featured Videos

What Is Type 1 Diabetes

Type 1 diabetes mellitus is defined by the autoimmune destruction of pancreatic beta cells, leading to an absolute — not relative — deficiency of insulin. Beta cells reside within the islets of Langerhans and are the body's sole source of endogenous insulin. When the immune system destroys them, glucose cannot be transported into peripheral cells (muscle, fat, liver) because insulin is required for this process in most tissues. Blood glucose rises unchecked (hyperglycemia), and the body, perceiving itself to be starving despite abundant glucose in the bloodstream, shifts into a catabolic state: fats are mobilized and broken down into free fatty acids, which the liver converts into ketone bodies. If untreated, this progression leads to diabetic ketoacidosis (DKA), a life-threatening metabolic emergency.

T1DM represents 5–10% of all diabetes diagnoses globally. It is most commonly diagnosed between the ages of 4 and 14, with peak incidence around puberty, but roughly 25–50% of new T1DM diagnoses now occur in adults over 30. This adult-onset pattern is important because adult-onset T1DM is frequently misclassified as type 2 diabetes — the patient may not be obese, may not respond to oral agents, and may experience DKA after a period of apparent "type 2" management.

A related but distinct entity is latent autoimmune diabetes in adults (LADA), sometimes called type 1.5 diabetes. LADA shares the autoimmune mechanism of T1DM but progresses more slowly — patients retain partial beta cell function for months to years before becoming insulin-dependent. They typically test positive for diabetes-associated autoantibodies (particularly GAD65) but are initially managed as type 2 because they are older and not acutely ill at presentation. The critical distinction matters clinically: sulfonylureas may accelerate beta cell loss in LADA, and insulin should be started earlier.

The fundamental metabolic difference between T1DM and T2DM is this: T2DM involves progressive insulin resistance (cells stop responding to insulin) combined with a relative insulin deficiency as the beta cells eventually tire; T1DM involves absolute insulin deficiency because the beta cells are gone. This is why oral glucose-lowering medications that work by stimulating insulin secretion (sulfonylureas) or improving insulin sensitivity (metformin) are insufficient as sole therapy in T1DM — there is no insulin left to stimulate, and no sensitivity to restore. Exogenous insulin is not optional; it is a survival requirement.

Back to Table of Contents

Genetics and Risk Factors

T1DM has a clear genetic predisposition, but it is not a simple Mendelian disorder. The monozygotic twin concordance rate is approximately 50%, confirming that while genetics is necessary, environment plays an equally decisive role. The disease results from a combination of susceptibility alleles — primarily in the human leukocyte antigen (HLA) system — and environmental exposures that trigger the autoimmune cascade in genetically primed individuals.

HLA Class II: The Dominant Genetic Risk

The HLA region on chromosome 6p21 accounts for approximately 40–50% of the genetic risk for T1DM. Specifically, two haplotypes confer the greatest susceptibility:

Individuals who are heterozygous for both DR3-DQ2 and DR4-DQ8 carry the highest risk — approximately 1 in 20 lifetime risk for T1DM in the general population, rising substantially if a first-degree relative is also affected. In contrast, HLA-DR2-DQ6 (DRB1*15:01-DQB1*06:02) is strongly protective and is rarely found in T1DM patients. These HLA molecules shape which peptide antigens are presented to T cells during thymic selection and peripheral immune responses; variants that present self-antigens (like proinsulin fragments) too weakly allow autoreactive T cells to escape deletion.

Non-HLA Susceptibility Loci

Genome-wide association studies have identified more than 60 non-HLA loci contributing to T1DM risk. Key among them:

Family Risk Estimates

Environmental Triggers

Genetics loads the gun; environment pulls the trigger. Leading candidate environmental factors include:

Global T1DM incidence is rising at 3–4% per year, particularly in lower-risk populations and younger age groups. This rate of increase far outpaces any plausible genetic shift, implicating accelerating environmental change — altered diet, microbiome disruption, and reduced infectious exposures — as driving forces.

Back to Table of Contents

Pathogenesis and Autoimmunity

Understanding how T1DM develops requires understanding the normal architecture of the islet and how the immune system dismantles it over months to years before clinical symptoms appear.

Normal Pancreatic Islet Architecture

The islets of Langerhans are clusters of endocrine cells scattered throughout the exocrine pancreas. Each islet contains:

In T1DM, the autoimmune attack is highly selective — alpha cells are largely spared even as beta cells are destroyed, which is why patients with T1DM have unchecked glucagon secretion relative to insulin, amplifying hyperglycemia.

The Autoimmune Cascade

The precise initiating event remains incompletely understood, but current models propose the following sequence:

  1. Environmental trigger (viral infection, microbiome disruption) activates innate immune cells near or within the pancreas
  2. Beta cell antigens (proinsulin fragments, GAD65, IA-2, ZnT8) are presented to naive T cells by antigen-presenting cells in pancreatic lymph nodes
  3. In genetically susceptible individuals (HLA DR3/DR4, PTPN22 variants), autoreactive CD4+ helper T cells and CD8+ cytotoxic T cells escape negative selection and peripheral tolerance mechanisms
  4. Insulitis develops: a histological finding of islet infiltration by CD8+ cytotoxic T lymphocytes, CD4+ T helper cells, macrophages, natural killer cells, and B cells
  5. CD8+ T cells kill beta cells via perforin/granzyme cytotoxicity and Fas-FasL-mediated apoptosis; macrophages contribute pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma) that further damage islets
  6. Autoantibodies are produced by B cells — these are markers of the autoimmune process but may also contribute to antigen presentation and amplification

Molecular Mimicry and Bystander Activation

Molecular mimicry is the best-studied mechanism linking viral infection to autoimmunity. Coxsackie B4 VP1 protein contains a sequence (PEVKEK) highly similar to a region of GAD65 (PEVKEK at residues 250–273). An immune response generated against the virus could theoretically cross-react with the beta cell enzyme. Similar mimicry has been proposed between rotavirus VP7 and IA-2.

Bystander activation is a complementary mechanism: viral replication in or near islets releases inflammatory cytokines and damage-associated molecular patterns (DAMPs) that non-specifically activate resident immune cells, lowering the threshold for autoreactive T cell activation without requiring direct antigenic mimicry.

Progressive Beta Cell Loss and the Honeymoon Period

The autoimmune process begins years to decades before clinical diagnosis. By the time a patient presents with symptoms of T1DM, approximately 70–90% of beta cell mass has been destroyed. The remaining 10–30% still produces some insulin, which is why newly diagnosed patients often experience a honeymoon period (partial remission) lasting weeks to months after starting insulin therapy. During this phase, residual beta cells recover some function — insulin requirements drop substantially, and glycemic control is easier. The honeymoon ends as the autoimmune process completes its destruction of remaining beta cells. Preserving this residual function longer is an active therapeutic goal, as even small amounts of C-peptide production are associated with fewer hypoglycemia episodes and better long-term vascular outcomes.

Back to Table of Contents

Autoantibodies and Stages of T1DM

One of the most important advances in T1DM research over the past three decades has been the identification of autoantibodies that appear in the blood years before any clinical symptoms — and the recognition that T1DM follows a predictable staged progression that can be detected and potentially interrupted.

The Key Autoantibodies

Four autoantibodies are currently used in clinical and research screening:

The presence of a single autoantibody carries modest risk of progression. The presence of two or more autoantibodies dramatically increases risk: studies from the TEDDY and DIPP cohorts show that children with two or more antibodies have a ~70% 10-year risk of progressing to clinical T1DM.

ADA Staging of T1DM

In 2015, the JDRF, the Endocrine Society, and the ADA formally adopted a three-stage model of T1DM (building on work by Insel et al.):

This staging framework is not merely academic. It enables:

  1. Identification of at-risk individuals through family screening programs (TrialNet, TEDDY, Fr1da)
  2. Enrollment in intervention trials aimed at delaying progression (teplizumab, antigen-specific immunotherapy)
  3. FDA approval of teplizumab specifically for stage 2 T1DM — delaying the onset of stage 3 by a median of ~2 years

The TrialNet Pathway to Prevention study is the premier family screening program in the United States — offering free autoantibody screening to relatives of people with T1DM. Identifying stage 1 or 2 disease opens access to clinical trials and, now, to approved therapy with teplizumab.

Back to Table of Contents

Diagnosis

Diagnosing diabetes itself uses standard ADA criteria. Distinguishing T1DM from T2DM requires additional workup, particularly in adults where the clinical presentation can be ambiguous.

Standard Diabetes Diagnostic Criteria (ADA)

Any one of the following is sufficient to diagnose diabetes (confirmed on a second day unless symptoms are unequivocal):

Distinguishing T1DM from T2DM

In children presenting with acute hyperglycemia or DKA, T1DM is assumed until proven otherwise. In adults, the distinction requires active investigation:

Presentation in Children vs. Adults

In children, 30–40% of new T1DM diagnoses present with diabetic ketoacidosis — often because the classic "polyuria, polydipsia, weight loss" symptoms were overlooked or attributed to other causes. In adults, the presentation is more heterogeneous: some present acutely with DKA, but many present with milder hyperglycemia and are misclassified as T2DM for months to years before the true diagnosis becomes apparent when oral agents fail and insulin is urgently required.

Genetic HLA typing can clarify risk but is not standard clinical practice; it is primarily used in research screening (TrialNet) and in counseling families of newly diagnosed patients.

Back to Table of Contents

Diabetic Ketoacidosis (DKA)

Diabetic ketoacidosis is a medical emergency defined by the triad of hyperglycemia, ketoacidosis, and ketonemia. It is most common in T1DM — where absolute insulin deficiency removes the brake on ketogenesis — but can also occur in T2DM under conditions of severe physiological stress.

Pathophysiology

The metabolic cascade of DKA begins with absent or severely deficient insulin:

  1. No insulin → glucose cannot enter cells. Despite high blood glucose, cells sense starvation.
  2. Counter-regulatory hormone surge: glucagon, cortisol, catecholamines, and growth hormone all rise. These hormones amplify hyperglycemia by driving hepatic glycogenolysis and gluconeogenesis.
  3. Lipolysis: without insulin's anti-lipolytic effect, adipose tissue releases massive amounts of free fatty acids (FFAs) into the circulation.
  4. Ketogenesis: the liver, flooded with FFAs and driven by glucagon, produces ketone bodies — acetoacetate, beta-hydroxybutyrate (BHB), and acetone. BHB is the predominant species (ratio 3:1 BHB:acetoacetate in DKA).
  5. Metabolic acidosis: ketoacids dissociate, releasing H+ ions and consuming bicarbonate, producing a high anion-gap metabolic acidosis.
  6. Osmotic diuresis: hyperglycemia causes glucosuria, driving water and electrolyte losses. Profound dehydration (average 3–5 liters fluid deficit) and electrolyte depletion follow.

Precipitants

Clinical Presentation

Patients develop:

Laboratory Findings

Classic DKA criteria: blood glucose >250 mg/dL (can be lower, especially with SGLT2 inhibitors); arterial pH <7.30; serum bicarbonate <18 mEq/L; anion gap >12; positive serum or urine ketones.

The most clinically dangerous laboratory finding is the potassium paradox: at presentation, serum potassium may appear normal or even elevated — despite total body potassium being severely depleted. Acidosis drives potassium out of cells in exchange for H+ ions, temporarily raising serum K. When insulin is administered, it drives potassium back into cells; if serum K was already low (or even low-normal), this can precipitate life-threatening hypokalemia. Serum potassium must be measured before starting insulin. If K <3.5 mEq/L, hold insulin and replace potassium first.

Treatment Protocol

Management of DKA has three simultaneous pillars:

  1. IV fluid resuscitation: Normal saline (0.9% NaCl) initially; transition to 0.45% NaCl once hemodynamic stability is restored; add dextrose when glucose falls to ~200–250 mg/dL (to allow continued insulin administration without hypoglycemia while DKA clears)
  2. Insulin infusion: Regular insulin IV at 0.1 units/kg/hour (or 0.14 units/kg/hr without bolus); do NOT start until K ≥3.5 mEq/L. The goal is gradual glucose reduction (50–75 mg/dL/hr) and anion gap closure.
  3. Potassium replacement: Add 20–40 mEq/L to IV fluids once K <5.5 mEq/L and patient is urinating. Monitor K every 2 hours. Target K 4–5 mEq/L throughout insulin infusion.

DKA is considered resolved when: pH >7.30, bicarbonate >18 mEq/L, and anion gap <12. Transition to subcutaneous insulin when the patient is eating and DKA criteria are met; overlap IV and SC insulin by 1–2 hours to prevent rebound ketoacidosis.

Bicarbonate infusion is generally avoided unless pH <6.9 (risk of paradoxical CNS acidosis and hypokalemia). Cerebral edema is a rare but catastrophic complication of DKA treatment, most common in children — monitor neurological status and avoid overly rapid fluid administration or glucose correction.

Hyperosmolar Hyperglycemic State (HHS)

HHS is the T2DM counterpart of DKA. It features extreme hyperglycemia (often >600 mg/dL), profound hyperosmolarity (serum osmolality >320 mOsm/kg), minimal ketonemia (residual insulin prevents significant ketogenesis), and frequently severe alteration of consciousness. Fluid deficits are much larger than in DKA (often 8–12 liters). Mortality is higher than DKA (10–20% vs <5%). Treatment prioritizes aggressive fluid resuscitation and gradual correction of hyperglycemia and osmolality.

Back to Table of Contents

Treatment and Insulin Therapy

Insulin is the cornerstone and the lifesaving necessity of T1DM management. Unlike T2DM, where insulin is one of several possible therapies, in T1DM there is no substitute — oral agents cannot compensate for absent beta cell function, and without insulin, DKA and death follow within days to weeks.

Insulin Pharmacology: Types and Timing

Modern insulin therapy uses analogs engineered for specific pharmacokinetic profiles:

Insulin Regimens

Two main regimens are used in T1DM:

Multiple Daily Injections (MDI): one or two injections of long-acting basal insulin (typically once daily at bedtime or morning) combined with rapid-acting prandial boluses before each meal. MDI requires patients to count carbohydrates and calculate insulin doses using their insulin-to-carbohydrate ratio (e.g., 1 unit covers 15g carbohydrate) and insulin sensitivity factor (correction factor — e.g., 1 unit drops glucose by 50 mg/dL). This regimen allows considerable flexibility but demands active self-management.

Continuous Subcutaneous Insulin Infusion (CSII) — insulin pump: a small programmable device worn on the body delivers rapid-acting insulin continuously via a subcutaneous cannula. Basal rates can be programmed to vary hour by hour (e.g., lower overnight, higher at dawn). Boluses are administered at meals. Pump therapy allows more precise insulin delivery, is particularly valuable for variable activity levels, and significantly improves glycemic control and quality of life in many patients. Risks include pump malfunction (leading to ketoacidosis within hours if undetected) and site infections.

Carbohydrate Counting and Dose Calculation

Effective mealtime dosing requires matching insulin to carbohydrate intake. Patients learn to:

  1. Count grams of carbohydrate in a meal
  2. Calculate the prandial dose: carbs ÷ insulin-to-carb ratio
  3. Add a correction dose if pre-meal glucose is above target: (current glucose − target glucose) ÷ insulin sensitivity factor

Hypoglycemia

Hypoglycemia is the most common and most feared acute complication of insulin therapy. It occurs when insulin dose exceeds the body's glucose needs — after missed meals, unexpected exercise, alcohol intake, or simply imprecise dosing. The American Diabetes Association defines hypoglycemia as:

Adrenergic symptoms (tremor, palpitations, diaphoresis, anxiety) typically precede neuroglycopenic symptoms (confusion, slurred speech, seizure, coma). Hypoglycemia unawareness — loss of adrenergic warning symptoms after years of T1DM — dramatically increases the risk of severe events and is an indication for CGM and/or closed-loop systems.

Treatment of mild-moderate hypoglycemia: the 15-15 rule — 15 grams of fast-acting carbohydrate (4 oz orange juice, 3–4 glucose tablets, regular soda), recheck glucose in 15 minutes, repeat if still <70. For severe hypoglycemia with loss of consciousness: injectable or intranasal glucagon (Baqsimi nasal powder, Gvoke autoinjector); bystander/caregiver training essential.

Glycemic Targets

ADA 2023 targets for most non-pregnant adults with T1DM: HbA1c <7%; preprandial glucose 80–130 mg/dL; postprandial glucose <180 mg/dL. Time-in-Range (TIR, 70–180 mg/dL): >70% of readings. Time below range (<70 mg/dL): <4%. These targets are individualized — patients with hypoglycemia unawareness or significant comorbidities may use less stringent goals; pregnant women use tighter targets.

Back to Table of Contents

Continuous Glucose Monitoring and Closed-Loop Systems

The evolution from intermittent fingerstick glucose monitoring to real-time continuous glucose monitoring (CGM) represents one of the most transformative advances in T1DM management of the past two decades. CGM systems measure interstitial glucose every 1–5 minutes, displaying trends and enabling automated alarms for impending hypoglycemia or hyperglycemia — fundamentally changing what patients know about their glucose at any given moment.

CGM Technology and Devices

CGM sensors use an enzymatic electrochemical reaction (glucose oxidase or glucose dehydrogenase) to measure glucose in the interstitial fluid of the subcutaneous tissue. Because interstitial glucose lags blood glucose by approximately 5–15 minutes during rapid glucose changes, CGM values are most accurate during stable periods; the "rate of change" arrow (showing whether glucose is rising, falling, or stable) is as clinically important as the absolute value.

Leading devices:

The landmark DIAMOND trial (Beck et al., JAMA 2017) demonstrated that CGM use in T1DM patients on MDI therapy significantly reduced HbA1c by 0.6% compared to fingerstick monitoring, with reductions in time below range as well. Time in range improvements translate directly to reductions in microvascular complications.

Automated Insulin Delivery (AID) — Closed-Loop Systems

Automated insulin delivery systems — colloquially called "artificial pancreas" systems — integrate three components: a CGM, an insulin pump, and a control algorithm that automatically adjusts insulin delivery in response to glucose values and trends. This closes the loop that previously required manual patient intervention at every step.

Currently approved AID systems in the US include:

The pivotal DCLP3 trial (Brown et al., NEJM 2019) demonstrated that Control-IQ increased time-in-range from 55% to 71% (a 16 percentage-point improvement) over 6 months compared to sensor-augmented pump therapy alone, with significant reductions in time below range and HbA1c. Improvements in nocturnal hypoglycemia were particularly striking.

All current approved systems are hybrid closed-loop — they still require the patient to announce meals and deliver prandial boluses. Fully closed-loop systems (no meal announcement required) are in advanced clinical trials; the iLet's meal-announcement-only design is a significant step toward full automation.

CGM and AID systems are particularly impactful in children: they reduce DKA episodes, severe hypoglycemia, and parental overnight anxiety — while improving school performance and quality of life.

Back to Table of Contents

Novel and Emerging Therapies

T1DM has historically been managed by replacing what the immune system destroyed. A new era of therapies aims to prevent that destruction — or to biologically replace beta cell mass. Several have now reached clinical approval or late-stage trials.

Teplizumab (Tzield) — First Disease-Modifying Therapy

In November 2022, the FDA approved teplizumab (Tzield, Provention Bio/Sanofi) as the first-ever disease-modifying therapy for T1DM — specifically to delay the onset of stage 3 T1DM in adults and children 8 years and older who have stage 2 T1DM (two or more autoantibodies + dysglycemia, no clinical symptoms).

Teplizumab is an anti-CD3 monoclonal antibody administered as a 14-day intravenous infusion. CD3 is a signaling component of the T cell receptor complex. By partially engaging and functionally modifying autoreactive T cells, teplizumab induces a state of T cell "exhaustion" (upregulation of TIGIT and other exhaustion markers) and shifts the balance toward regulatory T cells (Tregs) — partially restoring the immunological tolerance that T1DM has disrupted.

The pivotal At-Risk Clinical Trial in New-Onset Type 1 Diabetes (At-RISK, also known as TN-10) conducted through TrialNet demonstrated a median 2-year delay in progression from stage 2 to stage 3 T1DM compared to placebo. At 5 years, 50% of teplizumab-treated patients had not yet developed stage 3 T1DM, compared to only 22% of placebo-treated patients (Herold et al., NEJM 2019). Subsequent analysis showed preserved C-peptide and beta cell function in treated patients.

Teplizumab does not cure T1DM or prevent it indefinitely — it delays it. But a 2-year delay in insulin dependence during childhood has profound implications for quality of life, CGM/AID technology trajectory, and the window for additional immunotherapy. Identifying stage 2 patients through family screening (TrialNet) is now a clinical imperative.

Islet Cell Transplantation (Edmonton Protocol)

Islet transplantation offers the possibility of restoring endogenous insulin secretion and insulin independence. In the landmark Edmonton Protocol (Shapiro et al., NEJM 2000), cadaveric donor islets were isolated, purified, and infused into the portal vein of T1DM patients with recurrent severe hypoglycemia. All 7 initial patients achieved insulin independence — a dramatic proof of concept. Subsequent multicenter trials showed insulin independence rates of approximately 50–60% at 5 years, with the remainder maintaining partial function reducing hypoglycemia risk even without full independence.

Major limitations include: (1) dependence on cadaveric donors — only 1–2 islet transplants per year per center are possible given the donor shortage; (2) the need for lifelong immunosuppression to prevent graft rejection — with attendant risks of infection, malignancy, and nephrotoxicity; (3) gradual islet graft failure over years, requiring repeat transplantation. Islet transplantation remains a niche therapy reserved for carefully selected patients with severe hypoglycemia unawareness or extreme glycemic instability at specialized centers.

The TOTAL trial (transplantation or insulin therapy in type 1 diabetes) is a multicenter randomized trial comparing allogenic islet transplantation to best medical therapy in patients with recurrent severe hypoglycemia, with results expected to further define the role of this intervention.

Stem Cell-Derived Beta Cells

The donor shortage that limits islet transplantation could theoretically be solved by generating unlimited beta cells from stem cells. Vertex Pharmaceuticals is leading this approach with VX-880 — a stem cell-derived, fully differentiated islet cell product.

Phase 1/2 trial results in 2022–2023 showed that VX-880 (delivered via portal vein infusion, like islets) produced insulin in patients, with some achieving insulin independence at 12 months. Crucially, patients still require systemic immunosuppression. A parallel program ("VX-264") is testing the same stem cell-derived islets encapsulated in an implantable device designed to protect them from immune attack — potentially eliminating the need for immunosuppression. Early human implants are underway.

SGLT2 Inhibitors as Adjuncts in T1DM

Sodium-glucose cotransporter-2 (SGLT2) inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga) reduce blood glucose by blocking glucose reabsorption in the kidney, causing glucosuria. The FDA has approved specific lower doses of empagliflozin and dapagliflozin as adjuncts to insulin in T1DM adults inadequately controlled on insulin alone. Benefits include HbA1c reduction (~0.4–0.5%), body weight reduction, and blood pressure reduction.

However, SGLT2 inhibitors in T1DM carry a significant risk of euglycemic DKA — ketoacidosis occurring with only modestly elevated blood glucose (often <250 mg/dL), which can delay recognition. The mechanism: SGLT2 inhibition reduces insulin requirements (less glucose to cover), lowering the basal insulin dose; if insulin is then further reduced or a physiological stress occurs (fasting, exercise, infection), ketogenesis proceeds despite "acceptable" glucose levels. Patients and clinicians must be educated about this risk, and SGLT2 inhibitors should be held before surgical procedures, prolonged fasting, or major illness.

Additional Emerging Approaches

Back to Table of Contents

Research Papers

  1. Atkinson MA, Eisenbarth GS, Michels AW. "Type 1 diabetes." Lancet. 2014;383(9911):69-82. PMID 24206560
  2. Ziegler AG et al. "Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children." JAMA. 2013;309(23):2473-9. PMID 23680374
  3. Herold KC et al. "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes." N Engl J Med. 2019;381(7):603-613. PMID 30007553
  4. Sims EK et al. "Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals." Sci Transl Med. 2021;13(615):eabc8980. PMID 34613818
  5. Beck RW et al. "Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections." JAMA. 2017;317(4):371-378. PMID 28283083
  6. Brown SA et al. "Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes." N Engl J Med. 2019;381(18):1707-1717. PMID 31618560
  7. Shapiro AM et al. "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen." N Engl J Med. 2000;343(4):230-8. PMID 10935967
  8. Insel RA et al. "Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association." Diabetes Care. 2015;38(10):1964-74. PMID 25504028
  9. ElSayed NA et al. "Standards of Care in Diabetes — 2023." Diabetes Care. 2023;46(Suppl 1):S1-S4. PMID 36507639
  10. Atkinson MA, Bluestone JA, Eisenbarth GS et al. "How does type 1 diabetes develop? The notion of homicide or beta-cell suicide revisited." Diabetes. 2011;60(5):1370-9. PMID 22051897
  11. Battaglia M et al. "Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes." Diabetes Care. 2020;43(1):5-12. PMID 33541788
  12. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. "Current Concepts on the Pathogenesis of Type 1 Diabetes — Considerations for Attempts to Prevent and Reverse the Disease." Diabetes Care. 2015;38(6):979-88. PMID 26030227

Additional PubMed searches:

  1. Type 1 diabetes autoimmunity and pathogenesis
  2. Islet autoantibody screening and T1DM staging
  3. Teplizumab for T1DM prevention
  4. Closed-loop artificial pancreas systems in T1DM
  5. Diabetic ketoacidosis treatment

Back to Table of Contents

Connections

Back to Table of Contents